Thallium Toxicity Clinical Presentation

  • Author: G Patrick Daubert, MD; Chief Editor: Asim Tarabar, MD   more...
 
Updated: Apr 11, 2011
 

History

The clinical presentation of thallium toxicity can vary depending on the type, severity, and timeframe of the exposure. Acute thallium poisoning is primarily characterized by gastrointestinal symptoms, while neurologic findings predominate with chronic exposure. The neurologic manifestations tend to progress, even despite decreasing blood thallium levels. Thallium toxicity is characterized by a painful ascending peripheral neuropathy and alopecia; this clinical manifestation presents 2-3 weeks after an acute poisoning.[11]

  • Gastrointestinal symptoms: These symptoms predominate early, usually within the first 3-4 hours, and the most common symptom is severe, paroxysmal abdominal pain. It is important to remember that, unlike most other metal salts exposures, gastrointestinal findings in thallium toxicity may be mild or nonexistent, especially in chronic poisoning. Nausea, vomiting, constipation, and diarrhea are reported. Somewhat characteristic for thallium exposure, patients report abdominal pain, mild diarrhea, followed by constipation. The vomitus and stools are often bloody.
  • Neurologic symptoms: These symptoms usually appear 2-5 days postexposure and include severely painful, rapidly progressive, ascending peripheral neuropathies. Pain and paresthesias of the hands and the lower extremities, especially the soles of the feet, also predominate. Distal motor weakness occurs, with the lower limbs more affected than the upper limbs. Ataxia, tremor, athetosis, cranial nerve palsies, headache, seizures, insomnia, coma, and death may also occur.
  • Neuropsychological manifestations may include anxiety, confusion, delirium, hallucinations, and psychosis. Acute agitation and aggression, personality changes, depression, apathy, and confabulation have been observed in both adults and children. Psychosis and associated symptoms can occur with or without a psychiatric history.[12]
  • Ocular symptoms: Diplopia, abnormal color vision, and impairment of visual acuity may develop.[13] Other manifestations may include loss of the lateral half of the eyebrows, skin lesions on the lids, ptosis, seventh nerve palsy, internal and external ophthalmoplegia, and nystagmus. Noninflammatory keratitis, lens opacities, and optic atrophy due to toxic optic neuropathy also may occur.
  • Dermatologic symptoms: The first cutaneous signs are not specific and include scaling of the palms and soles and acneiform or pustular eruptions of the face.[14] During weeks 2-3, a sudden onset of hair loss quickly progresses to diffuse alopecia. The hair loss primarily affects the scalp, temporal parts of the eyebrows, the eyelashes, and the limbs. Less often, the axillary regions are affected. Hair discoloration may also occur. One month after the poisoning, Mees lines (transverse white lines on the nails) appear in the nail plate.[15] Other dermatologic findings include crusted eczematous lesions, hypohidrosis, anhidrosis, palmar erythema, stomatitis, and painful glossitis with redness of the tip of the tongue.[16]
  • Pulmonary symptoms: Some patients can experience pleuritic chest pain or tightness upon exposure. The mechanism for this particular symptom is unclear.
Next

Physical

Focus the physical examination primarily on the organ systems most commonly affected.

  • Perform careful abdominal and rectal examinations, including stool guaiac tests. Abdominal tenderness, hyperactive bowel sounds, mild guarding, and guaiac-positive stools can be found as early findings in thallium intoxication.
  • Perform a detailed neurologic examination, including a complete cranial nerve and visual field assessment.
    • All cranial nerves can be affected by thallium. Nystagmus (fourth and sixth CN involvement) and ptosis (third CN) may be present.
    • Decreased lower extremity strength with the lower limbs more affected than the upper limbs, hyperesthesia (especially of the soles of the feet), and decreased sensation to pinprick, touch, temperature, vibration, and proprioception in the fingers and toes may be present.
  • Perform a slit lamp examination and funduscopic examination, and carefully document visual acuity and color perception.
    • Decreased visual acuity with impairment of contrast sensitivity and tritanomaly (blue color vision defect) may be observed.[13]
    • In the early stages of thallium toxicity, funduscopic examination may reveal signs of an optic neuritis characterized by a red and poorly defined papilla. Continued thallium exposure causes atrophy of the optic nerve, which results in the development of a pale or white papilla.
    • Noninflammatory keratitis and lens opacities are also described.
  • Perform a skin and scalp examination.
    • Early skin findings include scaling of the palms and soles and acneiform lesions of the face.[14] Scalp alopecia, which is one of the most characteristic manifestations of thallium toxicity and is related to atrophy of the hair follicles, usually occurs 10-21 days postexposure.[11] In addition to the scalp, hair loss also occurs in the lateral eyebrows, the eyelashes, the limbs, and occasionally the axillary regions.
    • Hair roots may have dark brown or black pigmentation as a result of the accumulation of gaseous inclusions that diffract the light. With chronic exposure, these darker regions appear in bands, demonstrating multiple thallium exposures.
    • Approximately 1 month after thallium exposure, Mees lines (transverse white lines on the nails) appear in the nail plate.[15]
    • Other dermatologic findings include well-demarcated hyperkeratosis of the palms and soles, crusted eczematous lesions, hypohidrosis, anhidrosis, palmar erythema, crusted perioral dermatitis, painful glossitis with redness of the tip of the tongue, stomatitis, and hair discoloration.[16]
Previous
Next

Causes

  • Because it is odorless and tasteless, thallium has successfully been used worldwide as a rat poison and ant killer. It was restricted for household use in the United States in 1965 and banned commercially in 1975. Thallium is still commonly used as a rodenticide and insecticide in other countries resulting in severe unintentional poisoning. This is despite the World Health Organization recommendation against its use in 1973.
  • Thallium has been used as a pesticide in other countries, such as Africa, causing poisoning through contaminated foods. It has been discovered as a contaminant in some Chinese herbal medications.
  • In review of the American Association of Poison Control Centers Annual Report for toxic exposures from 2003-2006, unintentional thallium poisoning accounts for the majority of reported cases. There is likely an overlap of reports from patients with concerns of the radioactive contrast agent (thallium-201) following noninvasive cardiac studies. However, homicide and suicide represent a significant percentage of cases in the United States.
  • Thallium is toxic by cumulative intake; it can be absorbed through the skin, respiratory, and GI tracts. Therefore, besides oral ingestion, inhalation of contaminated dust during manufacture, sniffing what was thought to be cocaine, and skin absorption through protective gloves have all been reported as causes of thallium toxicity. In addition, cases of thallium intoxication by intravenous injection of contaminated heroin have been reported. However, the vast majority of cases result from oral exposures.
  • Because chronic thallium exposure mimics other disease, many cases of industrial thallium exposure most likely go unnoticed. On the other hand, accidental poisoning caused by direct contact with and careless handling of thallium-containing materials occurs more frequently.
  • Thallium is used most often in the semiconductor and optical industries. In addition, it is used in some industries for the production of photoelectric cells, scintillation counters, chemical catalysts, green-emitting fireworks, cement plants, and imitation jewelry.
  • Trace amounts of thallium are used as a radioactive contrast agent (thallium-201) to visualize cardiac function. The amount of carrier thallium used for this purpose is 4000 times less than the dose at which some toxic effects first appear in humans.
Previous
 
 
Contributor Information and Disclosures
Author

G Patrick Daubert, MD  Assistant Professor, Assistant Medical Director, Sacramento Division, California Poison Control System; Director of Clinical and Medical Toxicology Education, Department of Emergency Medicine, University of California, Davis Medical Center

G Patrick Daubert, MD is a member of the following medical societies: American College of Emergency Physicians, American College of Medical Toxicology, American Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

William K Chiang, MD  Associate Professor, Department of Emergency Medicine, New York University School of Medicine; Chief of Service, Department of Emergency Medicine, Bellevue Hospital Center

William K Chiang, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

John G Benitez, MD, MPH, FACMT, FAACT, FACPM, FAAEM,  Associate Professor, Department of Medicine, Medical Toxicology, Vanderbilt University Medical Center; Managing Director, Tennessee Poison Center

John G Benitez, MD, MPH, FACMT, FAACT, FACPM, FAAEM, is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, American College of Preventive Medicine, Society for Academic Emergency Medicine, Undersea and Hyperbaric Medical Society, and Wilderness Medical Society

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Asim Tarabar, MD  Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

References
  1. Mercurio M, Hoffman RS. Thallium. In: Goldfrank's Toxicologic Emergencies. 6th ed. 1998:1349-57.

  2. Mulkey JP, Oehme FW. A review of thallium toxicity. Vet Hum Toxicol. Oct 1993;35(5):445-53. [Medline].

  3. Saddique A, Peterson CD. Thallium poisoning: a review. Vet Hum Toxicol. Feb 1983;25(1):16-22. [Medline].

  4. Rusyniak DE, Furbee RB, Kirk MA. Thallium and arsenic poisoning in a small midwestern town. Ann Emerg Med. Mar 2002;39(3):307-11. [Medline].

  5. LaDou J. Metals. In: Occupational and Environmental Medicine. 2nd ed. 1997:429-30.

  6. Galván-Arzate S, Santamaría A. Thallium toxicity. Toxicol Lett. Sep 30 1998;99(1):1-13. [Medline].

  7. Hasan M, Ali SF. Effects of thallium, nickel, and cobalt administration of the lipid peroxidation in different regions of the rat brain. Toxicol Appl Pharmacol. Jan 1981;57(1):8-13. [Medline].

  8. Hultin T, Näslund PH. Effects of thallium (I) on the structure and functions of mammalian ribosomes. Chem Biol Interact. May 1974;8(5):315-28. [Medline].

  9. Hazardous Substances Data Bank [Internet]. Bethesda (MD): National Library of Medicine (US); [Last Revision Date 2005 Jun 23; cited 2005 Nov 17]. Thallium, Elemental; Hazardous Substances Databank Number: 4496.

  10. Atsmon J, Taliansky E, Landau M, et al. Thallium poisoning in Israel. Am J Med Sci. Nov 2000;320(5):327-30. [Medline].

  11. Moore D, House I, Dixon A. Thallium poisoning. Diagnosis may be elusive but alopecia is the clue. BMJ. Jun 5 1993;306(6891):1527-9. [Medline].

  12. McMillan TM, Jacobson RR, Gross M. Neuropsychology of thallium poisoning. J Neurol Neurosurg Psychiatry. Aug 1997;63(2):247-50. [Medline].

  13. Tabandeh H, Thompson GM. Visual function in thallium toxicity. BMJ. Jul 31 1993;307(6899):324. [Medline].

  14. Tromme I, Van Neste D, Dobbelaere F, et al. Skin signs in the diagnosis of thallium poisoning. Br J Dermatol. Feb 1998;138(2):321-5. [Medline].

  15. Saha A, Sadhu HG, Karnik AB. Erosion of nails following thallium poisoning: a case report. Occup Environ Med. Jul 2004;61(7):640-2. [Medline].

  16. Lu CI, Huang CC, Chang YC, Tsai YT, Kuo HC, Chuang YH, et al. Short-term thallium intoxication: dermatological findings correlated with thallium concentration. Arch Dermatol. Jan 2007;143(1):93-8. [Medline].

  17. Shamshinova AM, Ivanina TA, Yakovlev AA, et al. Electroretinography in the diagnosis of thallium intoxication. J Hyg Epidemiol Microbiol Immunol. 1990;34(2):113-21. [Medline].

  18. Hoffman RS. Thallium toxicity and the role of Prussian blue in therapy. Toxicol Rev. 2003;22(1):29-40. [Medline].

  19. Yang Y, Brownell C, Sadrieh N, et al. Quantitative measurement of cyanide released from Prussian Blue. Clin Toxicol (Phila). Oct-Nov 2007;45(7):776-81. [Medline].

  20. Miller MA, Patel MM, Coon T. Prussian blue for treatment of thallium overdose in the US. Hosp Pharm. 2005;40:796-7.

  21. Misra UK, Kalita J, Yadav RK, et al. Thallium poisoning: emphasis on early diagnosis and response to haemodialysis. Postgrad Med J. Feb 2003;79(928):103-5. [Medline].

  22. Ammendola A, Ammendola E, Argenzio F, et al. Clinical and electrodiagnostic follow-up of an adolescent poisoned with thallium. Neurol Sci. Aug 2007;28(4):205-8. [Medline].

  23. Montes S, Soriano L, Ríos C, et al. Endogenous thiols enhance thallium toxicity. Arch Toxicol. Oct 2007;81(10):683-7. [Medline].

  24. Sharma AN, Nelson LS, Hoffman RS. Cerebrospinal fluid analysis in fatal thallium poisoning: evidence for delayed distribution into the central nervous system. Am J Forensic Med Pathol. Jun 2004;25(2):156-8. [Medline].

  25. Talas A, Wellhöner HH. Dose-dependency of Tl+ kinetics as studied in rabbits. Arch Toxicol. May 1983;53(1):9-16. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.